The trial included 51 patients aged 50 and older, with results showing that 55% of treated patients experienced a reduction in lesion size of 30% or more. Additionally, the therapy was well-tolerated, with no serious adverse events reported. The findings suggest that OCU410 could significantly improve the treatment landscape for patients suffering from GA, a condition affecting millions worldwide.
Ocugen plans to initiate a Phase 3 registrational trial in the third quarter of 2026, aiming to file for Biologics License Applications (BLAs) for three products within three years. The company’s innovative approach targets multiple pathways involved in GA, potentially offering a one-time treatment solution that could alleviate the burden of frequent injections required by current therapies.
Dr. Shankar Musunuri, Chairman and CEO of Ocugen, expressed confidence in the results, stating, "We have confirmed robust treatment effect from a well-controlled Phase 2 trial of a genetic medicine for GA. Now we can move on to Phase 3 with a high degree of confidence. This moves us one step closer to bringing a transformative one-time treatment to GA patients globally who are desperately seeking rescue from vision loss."
The company’s commitment to advancing gene therapies for blindness diseases positions it as a leader in the biotechnology sector, with OCU410 representing a significant advancement in the treatment of GA. As the global prevalence of dAMD continues to rise, the need for effective therapies becomes increasingly critical, making Ocugen's developments particularly timely and relevant.
